|
|
|
|
|
|
|
|
|
12.06.26 - 11:24
|
FDA grants priority review for Roche′s Tecentriq combo sBLA (PBR)
|
|
|
The application covers patients with stage III colon cancer characterised by deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) or microsatellite instability-high (MSI-H). The FDA is anticipated to make
The post FDA grants priority review for Roche's Tecentriq combo sBLA appeared first on Pharmaceutical Business review....
|
|
|
|
|
11.06.26 - 10:30
|
Nurix Therapeutics-Aktie: 700 Millionen Dollar von Roche – winkt hier Großes? (Sharedeals)
|
|
|
Die Aktie von Nurix Therapeutics konnte sich nach unserem Kauftipp im Juli letzten Jahres zwischenzeitlich fast verdoppeln und profitiert derzeit von einer Kombination aus klinischen Fortschritten und einer milliardenschweren Partnerschaft mit Roche. Während das Biotechunternehmen seine führende BTK-Degrader-Plattform in der Onkologie weiter vorantreibt, eröffnen sich zugleich neue Wachstumschancen in den Bereichen Immunologie und Neurologie. Roche-Partnerschaft […]
The post Nurix Therapeutics-Aktie: 700 Millionen Dollar von Roche – winkt hier Großes? first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
11.06.26 - 07:03
|
FDA grants Priority Review for Roche′s Tecentriq for a certain type of stage III colon cancer (GlobeNewswire EN)
|
|
|
Basel, 11 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) filing for adjuvant Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy in stage III deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer, a type of tumour characterised by high mutation rates. The FDA has granted Priority Review and is expected to make a decision on the approval by 9 October 2026....
|
|
|
10.06.26 - 20:36
|
BigHat Biosciences Appoints Stefan Weigand as Chief Scientific Officer (Business Wire)
|
|
|
Veteran biologics leader brings more than 25 years of drug discovery experience and a track record of pipeline-scale impact at RocheSAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences, an AI-driven platform and therapeutics company, announced today the appointment of Stefan Weigand, PhD, as Chief Scientific Officer. Stefan joins from Roche, where he was Head of Large Molecule Research, overseeing a global team of approximately 350 scientists and the company's biologics, conjugates, and gene therapy pipeline from discovery through Phase I. Weigand's appointment comes as BigHat advances its AI-integrated drug design platform across multiple therapeutic programs. The company's closed-loop approach combines generative protein design with high-throughput experimental cycles, using Bayesian optimization to tune biologics across many competing design parameters at once.
Under Stefan's leadership at Roche, the biologics research organization doubled its output, reaching a steady-state delivery of five to s...
|
|
|
|
|
10.06.26 - 08:39
|
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery (GlobeNewswire EN)
|
|
|
Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biotechnology companies, technology companies and academic institutions, including Bristol Myers Squibb, Novo Nordisk, Bayer and Roche....
|
|
|
|
|
|
|
09.06.26 - 14:01
|
Champs d′Or en Beauce Augmente la Cible D′exploration Pour le Canal Paleoplacerien se Saint-Simon-les-Mines (The Newswire)
|
|
|
Le 9 juin 2026 - Montréal, Québec, Canada - Champs d'Or en Beauce (Beauce Gold Fields) (TSX Venture : BGF), ci-après « BGF » ou la « Société», a le plaisir d'annoncer les résultats d'une mise à jour de l'évaluation technique du canal paléoplacérien de Saint-Simon-les-Mines situé dans la région de la Beauce, au sud du Québec.
Patrick Levasseur, président et chef de la direction de Beauce Gold Fields, a commenté : « L'examen technique de juin 2026 améliore considérablement notre compréhension du système paléoplacérien de Saint-Simon-les-Mines. L'augmentation du potentiel tant en volume qu'en teneur appuie notre conviction que la paléovallée de la rivière Gilbert demeure l'une des occasions d'exploration aurifère placérienne les plus prometteuses de l'est de l'Amérique du Nord. Cette nouvelle interprétation renforce également le lien entre les dépôts paléoplacériens et les découvertes aurifères en roche encaissante de type Saddle Reef réalisées par la Soc...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
